Abstract The ability of a rigid α-Tn mimetic (compound 1) to activate murine invariant natural killer T (iNKT) and human natural killer (NK) cells, two subsets of lymphocytes involved in cancer immunesurveillance, was investigated. For this purpose, the mimetic 1 was properly conjugated to a stearic acid containing glycerol-based phospholipid (compound 5) to be presented, in the context of the conserved non polymorphic major histocompatibility complex class I-like molecules (CD1d), to iNKT cells. On the contrary, the mimetic 1 was conjugated to a multivalent peptide-based scaffold (compound 6) to induce NK cell activation.
Introduction
immunotherapy. These cells, even if they share some phenotypical and functional similarities, exert non-redundant and specific functions [14] .
In particular, human iNKT cells are a small proportion of T lymphocytes, expressing αβ T cell receptor (TCR) and natural killer (NK) cell lineage markers (e.g., CD161), which exhibit functional properties of both conventional T and NK cells [15] . They express an invariant TCR-α chain (Vα24-Jα18), paired with the semi-invariant TCR-β chain (Vβ11), that recognize lipid antigens when presented in the context of the conserved non polymorphic major histocompatibility complex class I-like molecules (CD1d) [16, 17] . Despite their invariant TCR, iNKT cells are able to recognize a diverse range of antigens, ranging from foreign microbials to endogenous lipids [18] , and rapidly and specifically respond against stimulation. Depending on the structure of lipid antigens and/ or cytokine stimuli iNKT cells can release a diverse range of cytokines (i.e., IFN-γ, IL-4) and chemokines (i.e., RANTES, eotaxin) [19] , and up-regulate different costimulatory molecules (i.e., CD28, CD40L) [20] , as well as cytotoxicity receptors (i.e., NKG2d) and mediators (i.e., perforine and granzyme) [21] . Through these signals iNKT cells can influence the activation/differentiation of dendritic cells (DCs), B and T lymphocytes, as well as NK cells, macrophages, and granulocytes. In the context of tumor immunity, iNKT cells play a critical role in immunosurveillance, even if the mechanisms underlying iNKT cell activation during tumor growth remain elusive.
On the other hand, NK cells are lytic lymphocytes, which mediate rapid effector responses without any priming [22, 23] . NK cells, compared to T or B lymphocytes, do not express clonally distributed receptors for antigens, [24, 25] but they have a plethora of germ-line encoded inhibitory/activating receptors [26] . In particular, the inhibitory receptors recognize the self-major histocompatibility complex class I (MHC-I) molecules preventing NK cell activation, while the activating receptors recognize the pathological cells, having the MHC-I molecules down-regulated [27] and/or the Bstress-inducedŝ elf proteins up-regulated [28] . NK cells are able to kill dangerous cells in few minutes by two main mechanisms: i) the interaction of specific cell surface ligands (e.g., FasL) with death receptors (e.g., Fas/CD95) expressed on transformed/ damaged cells; ii) the release of lytic granules, containing perforin and granzyme molecules, which can destroy target cells within hours trough cytotoxic activities similar to that of CD8+ cytotoxic T lymphocytes [29] . In addition, NK cells, once activated, release various cytokines/chemokines able to influence the functions of both adaptive and innate immune system [30] [31] [32] [33] . Recently, the immunological role of these cells appeared to be more complex, extending beyond the classical Binnate^time-frame towards functional features of adaptive immunity, such as longevity and immunological memory [34] [35] [36] .
On the basis of these evidences, the aim of the present study was to investigate the activity of the fully synthetic antigen 1 [37, 38] (Fig. 1 ) on iNKT and NK cell activation. Compound 1 is the first example of a conformationally constrained mimetic of the wellstudied α-Tn-antigen 2 [39] , a hapten expressed on different kind of cancer cells.
Recently, some of us successfully demonstrated that the Tn mimetic 1 (Fig. 1) , when properly functionalized on the carboxylic group with a suitable architecture, is able to trigger different immune cells and induce specific and long-lasting immune responses [40] . In particular: i) biocompatible and immunogenic iron oxide superparamagnetic nanoparticles 3 ( Fig. 1) , decorated with high density of the Tn mimetic 1, induce a specific macrophage activation [41] ; ii) the synthetic peptide-based glyco-cluster 4 ( Fig. 1) , which provided the multivalent presentation of the mimetic 1, elicits significant IgG/IgM mAb production and protection in mice affected by breast cancer [40] . The overall data confirm that the biological effect of the Tn-mimetic 1 can be modulated by changing the nonglycan portion of the conjugate.
Thus, following this concept and looking for an adequate and multi-target immune response, we here investigated the ability of the rigidified mimetic 1 to induce iNKT and NK cells activation. To gain this goal, both the glycoconjugates 5 and 6 were selected (Fig. 2) . In particular, the glycolipid 5, which consists of a stearic acid containing glycerol-based phospholipid conjugated to a residue of the Tn-mimetic 1, was chosen because of its ability to be presented by CD1d [42] to induce iNKT cell activation (T-cell-antigen presenting assay). On the contrary, taking into account that the multivalent presentation of 1 is important to modulate the induced immune response [40] the hexavalent glycopeptide 6 was also included in the study. Indeed, the glycopeptide 6 consists, of a cyclopeptide scaffold, termed regioselectively addressable functionalized template (RAFT) [43] , where six residues of 1, four on the upper face and two on the lower face of the RAFT, were conjugated to the lysine lateral chains. The ability of 6 to activate NK cells was assessed by measuring the expression of CD107a (degranulation assay).
Materials and methods

Materials
Reagents were purchased from commercial suppliers and used without purification. ESI-MS mass spectra were recorded on a LCQ-Fleet Ion Trap equipped with a standard Ionspray interface from Thermo Scientific. NMR spectra were recorded on Varian Gemini 300, Mercury Plus 400, Bruker AVANCE 500.
[α]D values were measured using a JASCO DIP-370 instrument. Protected amino acids and Fmoc-Gly-Sasrin resin were obtained from Advanced ChemTech Europe (Brussels, Belgium), Bachem Biochimie SARL (Voisins-LesBretonneux, France) and France Biochem S.A. (Meudon, France). PyBOP was purchased from France Biochem. Reaction progress was monitored by reversephase HPLC on Waters equipment using C 18 columns. Analytical and preparative separation was carried out at 1.0 mL/min (EC 125/3 nucleosil 300-5 C 18 ) and at 22 mL/min (VP 250/21 nucleosil 300-7 C 18 ) with UV monitoring at 214 nm and 250 nm using a linear A-B gradient (buffer A: 0.09% CF 3 CO 2 H in water; buffer B: 0.09% CF 3 CO 2 H in 90% acetonitrile). Cyclopeptides were analyzed by mass spectrometry using electrospray ionization on an Esquire 3000+ Bruker Daltonics in positive mode.
Chemistry
Synthesis of 9
To a stirred solution of TBTU (0.033 g, 0.104 mmol) in dry DMF (0.6 mL) NMM (0.012 mL, 0.104 mmol) was added. The mixture was left strirring for 15 min at r.t than a solution of 7 (0.024 g, 0.052 mmol) in DMF (0.4 mL) was added. The reaction mixture was left stirring for 10 min than a solution of 8 in dry CH 2 Cl 2 :CHCl 3 (3:1) was added. The mixture was warmed at 40°C for 1 h then cooled to r.t and left stirred for 15 h. After this time the reaction mixture was diluted with CH 2 Cl 2 (100 mL) and washed with H 2 O (1 × 10 mL), a 1 M solution of Triethylammonium bicarbonate (1 × 15 mL). The organic phase was dried over Na 2 SO 4 and concentrated to dryness to give a crude which was purified by flash chromatography on silica gel (AcOEt +0.1% NEt 3 ➔ DCM: MeOH 5: 1 + 0 . 1 % N E t 3 ) . C a t i o n c e x c h a n g e o f t h e triethylammonium salt of 9 with amberlite resin IR-120 Na + (CHCl 3 : MeOH 2:1) gave 9 (0.028 g, 0.023 mmol, 45%) as a glassy solid. H-1″'), 3.57 (d, J = 11.7 Hz, 1H, H-2), 3. 
Synthesis of 11
The aldehyde-containing cyclopeptide 13 [45] 
Synthesis of 12
Compound 12 has been prepared from 13 and hydroxylamine hydrochloride following the procedure described for 11. 
Cell cultures
Peripheral blood mononuclear cells (PBMC) were separated from venous blood of healthy volunteers after their informed consent by density gradient centrifugation using Lymphocite Separation Medium (LSM 1077) (GE Healtcare, Milan, Italy). After cell washing with Phosphate Buffer Saline (PBS) containing 0.1% Fetal Bovine Serum (FBS) (Carlo Erba, Milan, Italy) NK cells were isolated by magnetic separation technique using a negative selection isolation kit (Miltenyi Biotec, Bologna, Italy). Cells were then labelled with a cocktail of biotin-conjugated antibodies against lineage-specific antigens (CD3, CD4, CD14, CD15, CD19, CD36, CD123, CD235a) and labeled with a cocktail of MicroBeads (Miltenyi Biotec). Non-NK cells were separated using a Miltenyi Biotec MACS Column. NK cells were routinely purified to >90% by this method.
K562 cells are a highly undifferentiated human erythroleukemic cell line, which does not express MHC class I molecules [49] , and are a generous gift by Prof. M.C. Mingari (Department of Experimental Medicine, IRCCS AOU San Martino-IST, Genova, Italy).
Human CD1d transfected THP-1 and mouse FF13 iNKT hybridoma cells were kindly provided by Prof. Gennaro De Libero (Department of Research, Experimental Immunology, University Hospital Basel, Basel, CH). All cells were regularly cultured in RPMI-1640 complete growth medium, containing 10% heat inactivated FBS, 100 μg/ml kanamycin (SigmaAldrich, Milan, Italy), 1 mM sodium pyruvate (Lonza, Basel, Switzerland), 2 mM L-glutamime, 1% MEM amino acid solution (Lonza), 0.01 mM β-mercaptoethanol (GE healtcare), and cultured in a humidified atmosphere (5% CO 2 , 37°C).
Calcein AM assay
PBMC cells were labeled with 1 μM Calcein-AM (CAM) (Life Technologies, Monza, Italy) in serum-free PBS for 15 min at 37°C in the dark. After washing, labelled cells were seeded in 24-well plates and then treated with increasing concentrations (0.1-100 μM) of each compound for 24-48 h at 37°C in a humidified incubator. After incubation, the cells of each well were harvested, washed, labelled with propidium iodide (PI) (SigmaAldrich), and cell viability was measured by flow cytometry (FACSDiva Option, Becton Dickinson, Milan, Italy). Live cells were identified as CAM high /PI¯, whereas dead cells were CAM low /PI + . The viability was calculated by FACSDiva software and expressed as the percentage of CAM high /PI¯cell population relative to compound-untreated cells (controls).
NK cell degranulation assay
NK cell degranulation was measured in vitro by determining the expression of CD107a, the lysosomeassociated membrane protein-1 (LAMP-1), as previously described [49] . NK cells were untreated/treated with increasing concentrations (0.1-10 μM) of each compound for 24 h in presence of IL-2 (100 U/mL) (Peprotech, Rocky Hill, New Jersey, United States), a cytokine commonly used for NK cell activation [50] . Thereafter, NK cells were incubated with K562 cells at an effector/ tumor cell ratio of 1:1 for 1 h at 37°C in presence of anti-CD107a-Phycoerythrin (PE) (Miltenyi Biotec). Monensin (BD GolgiStop™ reagent, BD Bioscences, Milan, Italy) was added and cells incubated for 3 h at 37°C. Cells were washed and CD107a expression measured as Mean Fluorescence Intensity (MFI) by using FACSDiva software (BD Bioscience, Milan, Italy). To detect spontaneous NK cell degranulation, a negative control sample (NK cells without K562 target cells) was always included, while to measure the basal response of cells isolated NK cells were stimulated only with IL-2 (100 U/mL) (controls). As positive control we treated cells with 10 μM of 2,3-butanediol, which is a NK cell-activator at this concentration [51, 52] .
iNKT cell activation
THP-1 cells (5 × 10
4 /well) were incubated with increasing concentrations (0.01-100 μM) of each compound or (0.01-100 nM) of α-GalCer, in serum-free medium for 2 h at 37°C. iNKT hybridoma cells (1 × 10 5 /well) were then added, and the plates incubated in a 37°C, 5% CO 2 , humidified incubator for 48 h. Cell-free supernatants were collected and released IL-2 was measured by standard ELISA assay (R&D systems, Minneapolis, MN) using rat anti-mouse IL-2 mAbs and expressed in pg/ml (mean ± s.d.).
Statistical analysis
Results were expressed as means ± SEM of at least three independent experiments run in triplicate. Statistical significance was evaluated by the one-way ANOVA followed by Student's t-test for unpaired populations (Graph Pad Software, Inc., San Diego, USA). Differences were considered statistically significant when p ≤ 0.05.
Results and discussion
Chemistry
The glycolipid 5 was prepared starting from the peracetylated derivative 7 [37] (Scheme 1a). The tricyclic scaffold of 7 was efficiently obtained relying on an unconventional and totally stereoselective inverse electron-demand [4 + 2] Diels-Alder reaction between suitably protected glycals and α,α ' -dioxothiones as previously described by some of us [37] . The peracetylated derivative 7 (Scheme 1A) was coupled with the commercially available 1,2-distearoylsn-glycero-3-phosphoethanolamine 8 using TBTU [ N , N , N _ , N _ -t e t r a m e t h y l -O -( b e n z o t r i a z o l -1 yl)uraniumtetrafluoroborate; 2.0 equiv.] and N-methyl morpholine (NMM; 2.0 equiv.) as coupling agents. The resulting fully protected glycolipid 9 was obtained in 60% yield as sodium salt, after treatment with a cation-exchange resin (Amberlist IR120, Na + form). The α-galactosyl 9 was deprotected with a diluted solution of K 2 CO 3 to give 5 in 45% yield, after purification by column chromatography on Sephadex LH-20.
Glycopeptide 6 has been prepared from the cyclopeptide scaffold 10 [44] displaying six free lysines and the protected derivative 7 (Scheme 1B). The coupling reaction was performed with PyBOP as coupling reagent in DMF to afford the hexavalent acetylated compound that was subsequently deprotected with sodium methanoate in methanol. The resulting glycopeptide 6 was obtained in 51% yield after RP-HPLC purification Compounds 11 and 12 have been synthesized from cyclopeptide 13 [44] and α-ONH 2 -GalNAc [45] [46] [47] [48] 53] and hydroxylamine hydrochloride, respectively, using the oxime ligation strategy described earlier [46] [47] [48] 53] . The conjugation reaction occurred in water with 0.1% of TFA and the conversion of 13 was found quantitative in both cases within 2 h at 37°C. After RP-HPLC purification, compounds 11 and 12 were obtained in 76% and 60% yield, respectively. 
Biological assays
Cell viability
To evaluate the effect of compounds 1, 5, 6, 8, 11, 12 and α-OMe-GalNAc on cell viability human PBMC, containing a variable percentage of NK (from 2% to 18%), and iNKT cells (from 0.1 to 2%) were used [54, 55] . PBMC were labelled with CAM and incubated with increasing concentrations (0.1-100 μM) of each compound for 24/48 h. Cells not exposed to compounds were taken as negative controls. Cell viability, evaluated by FACS, always resulted ≥90% at all concentrations and times tested (see Fig. S1, S2 ), suggesting that all compounds under study are non-toxic for PBMC and useful for functional studies.
iNKT cell activation
To evaluate the ability of the glycolipid 5 to activate iNKT cells a T cell-antigen presenting assay was used. Mouse iNKT hybridoma cells (FF13; 5 × 10 4 cells/ well), selected for their ability to respond to alphagalactosylceramide (α-GalCer) presented by CD1d expressing cells [56] , were co-cultured with CD1d-transfected THP-1 cells (2.5 × 10 4 cells/well), previously (2 h) treated with increasing concentrations (0.01-100 μM) of glycolipid 5. Furthermore, the activity of this compound was compared with the 1,2-distearoyl-snglycero-3-phosphoethanolamine 8 and the α-OMeGalNAc (Fig. 3a) , while the α-GalCer (0.01-100 nM) was used as positive control for validation of the assay (Fig. 3b) .
IL-2 production, typically measured to assess the abilities of α-GalCer to stimulate human or murine iNKT cell hybridomas [57] , was evaluated in the cell culture media after 48 h of co-culture by ELISA. Figure 3a shows that, as expected, only compounds having a lipid moiety (both the 1,2-distearoyl-snglycero-3-phosphoethanolamine 8 and the glycolipid 5) induced IL-2 release in a concentration-dependent manner.
T h e m a xi m um e ff ec t s w e r e : 4 5 7 ± 4 7 an d 634 ± 23 pg/mL at 10 μM, and the EC 50 measured were 0.5 ± 0.02 and 0.7 ± 0.01, respectively. The ability of phospholipid 8 to induce iNKT cell activation has been previously reported by Wu et al., [58] and present data are consistent with this report. Conversely, both the α-OMe-GalNAc and the Tn-mimetic 1 failed in inducing iNKT cell activation at all concentrations tested.
Of note, when the Tn-mimetic antigen 1 was conjugated to the phospholipid 8 a significant increase (+ 40 ± 5%; P ≤ 0.01) in the IL-2 release was measured, compared to the phospholipid 8.
The overall data clearly demonstrate that the conjugation of Tn-mimetic 1 to a lipid architecture confers to the antigen the ability to activate murine iNKT cells.
NK cell degranulation
To determine the effect of the glycopeptide 6 on NK cell activity a short-term degranulation assay was performed, by measuring the expression of CD107a [51, 52] , a cell surface antigen whose expression well correlates with the NK killing activity [49] . The activity of the glycopeptide 6 was compared with that of the α-OMe-GalNAc, the Tn-mimetic 1, the RAFT-based glycopetide 11 containing six residue of GalNAc, and the hexavalent RAFT-based peptide scaffold 12 (-negative control). Cells treated with 10 μM of 2,3-butanediol, a well-known NK cell-activator [50] , were always taken as positive controls (black bar).
As shown in the Fig. 4 , both the α-OMe-GalNAc and the Tn mimetic 1 resulted effectively in inducing a higher CD107a expression compared to compounduntreated cells (negative controls, vertical black line). The maximum effects were: +65 ± 13% (P ≤ 0.01) and +74 ± 26% (P ≤ 0.05) at 1 μM, respectively. The conjugation of GalNAc or the Tn mimetic to RAFT peptide (compounds 6 and 11) did not improve cell responses in comparison to cells treated with monovalent un-conjugated antigens, probably because this type of scaffold is not able to increase the selectivity and the strength of receptor binding, a fundamental feature for eliciting efficient immune cell activations. Conversely, the RAFT-based peptide 12 resulted effective at all the concentrations tested.
The overall results suggest that a peptide RAFT is an unsuitable scaffold for the multivalent presentation of these type of molecules, since itself could interact with receptors, expressed on NK cells, specifically recognizing peptides.
From our data it is, however, reasonable to conclude that both α-OMe-GalNAc and Tn mimetic 1 are able to activate human NK cells, as 2,3-butanediol (positive control) does.
Conclusion
In summary, we reported here the synthesis of the glycolipid 5 and the hexavalent glycopeptide 6, containing one and six copies of the rigid α-Tn mimetic 1, respectively. From our data: i) all the tested compounds are biocompatible; ii) the Tn mimetic 1 activates human NK cells and, when suitably conjugated to a glycolipid, murine iNKT cells as well.
Since to induce a strong and efficient tumour immunesurveillance a complex cross-talk between the innate and adaptive immune system is strictly needed, the compound 1, able to activate both iNKT and NK cells, appears to be an appealing lead, useful to act as a linker between the two immune systems for promoting efficient immune responses. 
